Akazawa S
Dept. of Gastroenterology Saitama Cancer Center, Japan.
Gan To Kagaku Ryoho. 1992 Jul;19(7):963-9.
A phase II clinical trials of the combination of 5-FU and interferon (IFN) were reviewed. The treatment regimen was based on the method reported by Scott Wadler, et al: 5-FU was administrated as continuous infusion at 750 mg/m2/day for 5 consecutive days and as intravenous bolus at 750 mg/m2 weekly for 7 weeks beginning on day 12. IFN was administrated subcutaneously at 9 x 10(6) I.U three times a week during weeks 1 to 8. Although the mechanism of action remains to be elucidated, some studies in immunological, pharmacokinetics, or biochemical viewpoint were reported. In this paper, the mechanisms of action related to TS and TK were introduced in biochemical viewpoint. Furthermore, side effects of IFN/5-FU combination and dual modulation of 5-FU with IFN and LV were referred.
一项关于5-氟尿嘧啶（5-FU）与干扰素（IFN）联合使用的II期临床试验得到了综述。治疗方案基于斯科特·瓦德勒等人报道的方法：5-FU以750mg/m²/天的剂量连续输注5天，并从第12天开始每周静脉推注750mg/m²，共7周。IFN在第1至8周每周皮下注射3次，每次9×10⁶国际单位。尽管其作用机制仍有待阐明，但已有一些从免疫学、药代动力学或生物化学角度进行的研究报道。本文从生物化学角度介绍了与胸苷酸合成酶（TS）和胸苷激酶（TK）相关的作用机制。此外，还提及了IFN/5-FU联合使用的副作用以及IFN与亚叶酸（LV）对5-FU的双重调节作用。
